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ntracellular calcium is one of the important signals that
initiates the myogenic program. The calcium-activated
phosphatase calcineurin is necessary for the nuclear
import of the nuclear factor of activated T cell (NFAT)
family members, which interact with zinc ﬁnger GATA
transcription factors. Whereas GATA-6 plays a role in the
maintenance of the differentiated phenotype in vascular
smooth muscle cells (VSMCs), it is unknown whether the
calcineurin pathway is associated with GATA-6 and plays a
role in the differentiation of VSMCs. The smooth muscle–
myosin heavy chain (Sm-MHC) gene is a downstream
target of GATA-6, and provides a highly speciﬁc marker for
I
 
differentiated VSMCs. Using immunoprecipitation Western
blotting, we showed that NFATc1 interacted with GATA-6.
Consistent with this, NFATc1 further potentiated GATA-6–
activated Sm-MHC transcription. Induction of VSMCs to
the quiescent phenotype caused nuclear translocation of
NFATc1. In differentiated VSMCs, blockage of calcineurin
down-regulated the amount of GATA-6-DNA binding as
well as the expression of Sm-MHC and its transcriptional
activity. These ﬁndings demonstrate that the calcineurin
pathway is associated with GATA-6 and is required for the
maintenance of the differentiated phenotype in VSMCs.
 
Introduction
 
In response to vascular injury, vascular smooth muscle cells
(VSMCs)* undergo a dedifferentiation process referred to as
phenotypic modulation, become proliferative, and act as a
major component of thickened arterial intima. Thus, deter-
mining the molecular mechanisms of phenotypic modulation
is important for understanding mechanisms of vascular
disease such as atherosclerosis and restenosis after angioplasty.
Phenotype modulation is associated with changes in the
expression patterns of contractile proteins. For example, the
expression of smooth muscle–myosin heavy chain (Sm-MHC),
a well-characterized smooth muscle–specific contractile pro-
tein (Owens, 1995), decreases or is even absent in proliferat-
ing or dedifferentiated VSMCs (Nagai et al., 1989; Kuro-o
et al., 1991;
 
 
 
White et al., 1993). Therefore, in addition to
the usefulness of Sm-MHC as a highly specific marker for
the smooth muscle cell lineage, this protein is a potentially
useful marker for specifying the factors involved in the pro-
liferative/dedifferentiated or quiescent/differentiated SMC
phenotype. Our recent study has shown that a zinc finger
protein, GATA-6, binds to a GATA consensus motif in the
rat Sm-MHC promoter and activates this promoter in a
sequence-specific manner (Wada et al., 2000). The muta-
tion of this element decreases the Sm-MHC transcriptional
activity in differentiated VSMCs. GATA-6 is expressed in
VSMCs and is rapidly down-regulated by mitogen stimula-
tion (Perlman et al., 1998). Overexpression of GATA-6 in
proliferating VSMCs induces cell cycle arrest with a con-
comitant increase in the expression of cyclin-dependent kinase
inhibitor (Perlman et al., 1998). These findings demonstrated
that GATA-6 is involved in the maintenance of the quiescent
phenotype in differentiated VSMCs. However, the relation-
ship of GATA-6 to upstream signaling pathways is unknown.
In the skeletal muscle cell lineage, one of the important
signalings that initiates differentiation is intracellular calcium.
The total cell calcium increases during skeletal muscle differ-
entiation (Przybylski et al., 1989), whereas a decrease in in-
tracellular calcium inhibits differentiation (Salzberg et al.,
1995; Seigneurin-Venin et al., 1996). Recently, Friday et al.
(2000) have shown that calcium- and calcineurin-dependent
pathways are required for commitment of skeletal muscle
cells to differentiation. Calcineurin is a calcium-calmodulin–
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dependent serine-threonine phosphatase that activates tran-
scription of the nuclear factor of activated T cell (NFAT)
family, causing their translocation to the nucleus to initiate
transcription of cytokines involved in the immune response
(Batiuk and Halloran, 1997). The immunosuppressant
drugs cyclosporin A (CysA) and FK506 bind the immuno-
philin cyclophilin, forming a complex that binds the cal-
cineurin catalytic subunit and inhibits calcineurin’s ability to
activate NFAT transcription factors (Shaw et al., 1995; Loh
et al., 1996). Molkentin et al. (1998) have reported that a
zinc finger protein GATA-4 interacts and cooperates with
the NFAT family to activate the transcription of cardiac-spe-
cific genes such as B-type natriuretic peptide gene. These
findings prompted us to investigate whether a calcineurin
pathway connected with GATA-6 is involved in smooth
muscle–specific transcription. The present study investigated
the role of the calcineurin-GATA-6 pathway for the smooth
muscle–specific transcription in differentiated VSMCs.
 
Results
 
GATA-6 interacts with NFATc1
 
To determine whether GATA-6 and NFATc1 associate in
vivo, we performed immunoprecipitation, followed by West-
ern blotting. COS7 cells were transfected with an expression
plasmid encoding NFATc1 (pNFATc1) and one encoding
wild-type GATA-6 (pwtGATA-6). 48 h later, nuclear ex-
tracts derived from the transfected cells were immunoprecip-
itated with the anti-NFATc1 antibody as a positive control
(Fig. 1, lane 1), with normal rabbit IgG as a negative control
(Fig. 1, lane 2), or with the anti–GATA-6 antibody (Fig.
1, lane 3). These immunoprecipitates were then subjected
to Western blotting using the anti-NFATc1 antibody. As
shown in Fig. 1 (top panel, lane 3), an interaction between
wild-type GATA-6 and NFATc1 was observed even after ex-
tensive washing. To determine whether the interaction be-
tween GATA-6 and NFATc1 occurs through the zinc finger
domain of GATA-6, COS7 cells were transfected with an ex-
pression plasmid encoding mutant GATA-6 defective for the
zinc finger domain (p
 
 
 
ZFGATA-6) instead of pwtGATA-6.
Nuclear extracts were subjected to immunoprecipitation fol-
lowed by Western blotting as described above. As shown in
Fig. 1 (top panel, lane 6), no interaction was observed be-
tween mutant GATA-6 and NFATc1. The anti-NFATc1
antibody was stripped, and then the membrane was reprobed
with the anti–GATA-6 antibody. As shown in Fig. 1 (bot-
tom panel), expression levels of wild-type and mutant
GATA-6 before immunoprecipitation were similar among
all lanes (lanes 1–6). In addition, as shown in Fig. 1 (middle
panel), wild-type and mutant GATA-6 were similarly immu-
noprecipitated by the anti–GATA-6 antibody (lanes 3 and
6). These findings indicate that the zinc finger domain of
GATA-6 is required for the interaction with NFATc1.
 
GATA-6 and NFATc1 coactivate the Sm-MHC promoter
 
To determine whether GATA-6 and NFATc1 functionally
cooperate in vivo, we performed transient transfection as-
says in VSMCs. We cotransfected a chloramphenicol
acetyltransferase (CAT) expression vector driven by the
1346-bp Sm-MHC promoter together with a eukaryotic
expression plasmid encoding wild-type GATA-6 (pwt-
GATA-6), alone, or in combination with a vector encoding
NFATc1 (pNFATc1). The total amount of DNA was kept
constant by addition of pCMV
 
 
 
-gal. The transfection effi-
ciency was monitored by cotransfected pRSVluc activity.
48 h later, we measured the Sm-MHC reporter activity. As
shown in Fig. 2, the coexpression of NFATc1 and wild-
type GATA-6 induced a significant elevation of the level of
the reporter (lane 5) above the levels observed with either
NFATc1 (lane 4) or GATA-6 (lane 2) alone. To determine
whether coactivation by GATA-6 and NFATc1 requires
the zinc finger domain of GATA-6, we transfected an ex-
pression plasmid encoding mutant GATA-6 lacking the
zinc finger domain (p
 
 
 
ZFGATA-6) instead of pwtGATA-
6. Compatible with the inability of mutant GATA-6 to in-
teract with NFATc1, the coexpression of NFATc1 and
mutant GATA-6 did not coactivate the Sm-MHC pro-
moter (lane 6). Therefore, the zinc finger domain of
GATA-6 is required for coactivation of the Sm-MHC pro-
moter by GATA-6 and NFATc1 in VSMCs.
Figure 1.  NFATc1 interacts with GATA-6 through its zinc finger 
domain. COS7 cells were cotransfected with 6  g of pNFATc1 and 
6  g of either pwtGATA-6 or p ZFGATA-6 as indicated. Nuclear 
extracts derived from these cells were immunoprecipitated with the 
anti-NFATc1 antibody (lanes 1 and 4), with control IgG (lanes 2 and 
5), and with the anti–GATA-6 antibody (lanes 3 and 6). After elec-
trophoresis and electroblotting, the membrane containing immobi-
lized immunocomplexes was subjected to Western blotting using 
the anti-NFATc1 antibody (top panel). The anti-NFATc1 antibody 
was stripped and then the membrane was reprobed with the anti–
GATA-6 antibody (middle panel). Nuclear extracts before immuno-
precipitation were also subjected to Western blotting using the anti–
GATA-6 antibody (bottom panel). 
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Induction of the differentiated phenotype causes 
nuclear translocation of NFATc1
 
To examine which NFAT family members are expressed in
VSMCs, we performed Western blotting using human Bur-
kitt’s lymphoma-derived Ramos cells as a positive control.
As shown in Fig. 3, Ramos cells abundantly expressed all
of NFATc1-4. In contrast, VSMCs expressed a significant
amount of NFATc1 and a small amount of NFATc3.
NFATc2 and NFATc4 were not detected by our Western
blotting. To further examine changes in the subcellular local-
ization of NFATc1 in VSMCs by induction of the differenti-
ated phenotype, immunofluorescence staining was performed.
VSMCs were cultured in 5% serum with growth factors to
maintain the proliferative phenotype, or in 1% serum without
growth factors to induce the differentiated phenotype, in the
presence or absence of CysA (0.5 
 
 
 
g/ml). As shown in Fig. 4,
NFATc1 was detected in the cytoplasm of nearly all VSMCs
of the proliferative phenotype (A). However, induction of
these cells to the differentiated phenotype markedly changed
this localization and caused the nuclear translocation of
NFATc1 (Fig 4 B). This translocation was reversed by CysA
(Fig. 4 C) which blocks calcineurin. These findings suggest
that calcineurin is activated during VSMC differentiation.
 
Blockage of calcineurin down-regulates the Sm-MHC 
transcriptional activity in differentiated VSMCs
 
We investigated whether calcineurin plays a role in the tran-
scriptional activation of Sm-MHC gene during VSMC dif-
ferentiation. VSMCs were transfected with a luciferase (luc)
gene driven by the Sm-MHC promoter (Fig. 5 A, pwtSm-
MHCluc), or that containing the GATA site mutation
which abolishes the binding of GATA-6 (Fig. 5
 
 
 
B, pmutSm-
MHCluc). VSMCs were then cultured in 5% serum with
growth factors to maintain the proliferative phenotype (Fig.
5,
 
 
 
A, lanes 1–3, and B, lane 1), or in 1% serum without
growth factors to induce the differentiated phenotype (Fig.
5, A, lanes 4–6, and B, lane 2). As shown in Fig. 5
 
 
 
A (lanes 1
and 4), the transcriptional activity of the Sm-MHC pro-
moter increased by induction of the differentiated pheno-
type. However, as shown in Fig. 5
 
 
 
B (lanes 1 and 2), the mu-
tation of the GATA site within this promoter abolished the
activation. This is compatible with our previous report and
suggests a role of GATA-6 for VSMC differentiation. To ex-
amine the role of calcineurin in the transcriptional activation
of the wild-type Sm-MHC promoter, we administered dif-
ferentiation medium CysA (0.5 
 
 
 
g/ml) or FK506 (1 nM)
which blocks calcineurin. As shown in Fig. 5
 
 
 
A (lanes 5 and
6), CysA and FK506 inhibited the activation. However, nei-
ther CysA nor FK506 affected the wild-type Sm-MHC pro-
moter activity in proliferation medium (Fig. 5 A, lanes 2 and
3). The 
 
 
 
-actin promoter activity did not differ between
proliferation medium and differentiation medium (Fig. 5
 
 
 
C,
lanes 1 and 4) and was not affected either by CysA (Fig. 5 C,
lanes 2 and 5) or by FK506 (Fig. 5
 
 
 
C, lanes 3 and 6). These
findings demonstrate that calcineurin activation is required
Figure 2. NFATc1 activates the GATA-6–dependent Sm-MHC 
transcription. VSMCs were transfected with 2  g of a Sm-MHC CAT 
reporter; 0.1  g of pRSVluc; 2  g of either pNFATc1 or pCMV -gal; 
and 2  g of pwtGATA-6, p ZFGATA-6, or pCMV -gal as indicated. 
48 h later, the relative CAT activities (CAT/luc) were determined. 
The results are expressed as fold activation of the normalized CAT 
activities (CAT/luc) relative to that produced by cotransfection with 
the control  -galactosidase expression vector. The data shown are 
the mean   standard error of two independent experiments, each 
performed in duplicate. Figure 3.  Endogenous expression of NFATc1–4 in VSMCs. 
VSMCs were cultured in proliferation (P) medium (lane 1) or differ-
entiation (D) medium (lanes 2). Lysates from these cells and Ramos 
cells as a positive control were subjected to Western blotting using 
the anti-NFATc1 antibody, the anti-NFATc2 antibody, the anti-
NFATc3 antibody, the anti-NFATc4 antibody and the anti– -actin 
antibody, as indicated. 
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for the transcriptional activation of the Sm-MHC gene dur-
ing VSMC differentiation.
 
Blockage of calcineurin down-regulates GATA-6-DNA 
binding in differentiated VSMCs
 
To determine whether GATA-6-DNA binding in VSMCs is
modulated by the cellular phenotype change, and if so,
whether calcineurin activation is involved in this change, elec-
trophoretic mobility shift assays (EMSAs) were performed.
VSMCs were cultured in 5% serum with growth factors to
maintain the proliferative phenotype (Fig. 6,
 
 
 
A, lane 1 and C,
lane 1), or in 1% serum without growth factors (Fig. 6,
 
 
 
A,
lanes 2–5, and C, lanes 2 and 3) to induce the differentiated
phenotype. Nuclear extracts were probed with a radiolabeled
oligonucleotide containing the Sm-MHC GATA site in the
presence or absence of competitor DNAs (Fig. 6
 
 
 
A). Competi-
tion EMSAs revealed that a retarded band represented specific
binding, as evidenced by the fact that it was competed out by
an excess of unlabeled wild-type Sm-MHC GATA oligonucle-
otide (Fig. 6
 
 
 
A, lane 4), but not by the same amount of an oli-
gonucleotide containing the Sm-MHC GATA site with a mu-
tation (Fig. 6
 
 
 
A, lane 5). To further confirm that the retarded
band represents an interaction of the probe with GATA-6, we
performed a supershift experiment. As shown in Fig. 6
 
 
 
B, the
retarded band disappeared with administration of the anti–
GATA-6 antibody (lane 3), but not with either the anti–
GATA-4 antibody (lane 2) or normal rabbit IgG (lane 1).
These data indicate that the retarded band contains the com-
plex that specifically immunoreacts with the anti–GATA-6 an-
tibody. Notably, the amount of GATA-6-DNA binding in-
creased in nuclear extracts from VSMCs with the differentiated
phenotype (Fig. 6 A, lane 2), as compared with those from
VSMCs with the proliferative phenotype (Fig. 6
 
 
 
A, lane 1). In
contrast, the amount of SP-1-DNA binding did not differ
between the proliferative and differentiated phenotypes of
VSMCs (Fig. 6
 
 
 
C, lanes 1 and
 
 
 
2). To determine whether the
up-regulation of GATA-6-DNA binding in VSMCs is cal-
cineurin-dependent, VSMCs were cultured in differentiation
medium in the presence or absence of a therapeutic concentra-
tion (0.5 
 
 
 
g/ml) of CysA, which blocks calcineurin. The
amount of GATA-6-DNA binding in differentiated VSMCs
was down-regulated by CysA (Fig. 6
 
 
 
A, lane 3), whereas that of
SP-1-DNA binding was not altered by CysA (Fig. 6
 
 
 
C, lane 3).
The amount of GATA-6-DNA binding normalized with that
of SP-1-DNA binding was quantified and is shown in Fig. 6
D. The relative DNA binding amount of GATA-6 was signifi-
cantly reduced by CysA (Fig. 6 D, lane 3). These findings sug-
Figure 4.  Induction of the differentiated phenotype of 
VSMCs translocates NFATc1 into the nucleus in a cal-
cineurin-dependent manner. VSMCs were cultured in 
medium with growth factors and 5% serum to maintain 
the proliferative phenotype (A) or in medium with 1% se-
rum to induce the differentiated phenotype in the pres-
ence (C) or absence (B) of CysA (0.5  g/ml) for 48 h and 
subjected to immunofluorescence using the anti-NFATc1 
antibody. Bar, 20  m.
Figure 5.  CysA and FK506 inhibited the activation of the Sm-
MHC promoter by the induction of differentiated phenotype in 
VSMCs. Two  g of pwtSm-MHCluc (A), pmutSm-MHCluc (B) or p -
actinluc (C), and 0.1  g of pRSVCAT were cotransfected into 
VSMCs which were subsequently cultured in proliferation (P) me-
dium (A and C, lanes 1–3, and B, lane 1) or differentiation (D) me-
dium (A and C, lanes 4–6, and B, lane 2) in the presence of CysA (A 
and C, lanes 2 and 5, 0.5  g/ml) or FK506 (A and C, lanes 3 and 6, 
1 nM), or in their absence (A and C, lanes 1 and 4, and B, lanes 1 
and 2) as indicated. 48 h later, these cells were collected and the 
relative luc activity (luc/CAT) was determined. The relative luc ac-
tivity in the proliferative VSMCs was set at 100% in each experi-
ment. The data shown are the mean   standard error of two inde-
pendent experiments, each performed in duplicate. 
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gest that the up-regulation of GATA-6-DNA binding in
VSMCs is, at least in part, calcineurin dependent.
To examine changes in the expression of GATA-6 in VSMCs
by induction of the differentiated phenotype, Western blot
analysis was performed. As shown in Fig. 7, the expression of
GATA-6 was slightly up-regulated by induction of the differen-
tiated phenotype (lane 2) as well as NFATc1. The administra-
tion of CysA (lane
 
 
 
3, 0.5 
 
 
 
g/ml) and FK506 (lane 4, 1 nM) did
not affect their expression in differentiated VSMCs. Expression
levels of GATA-6 and NFATc1 were quantified and normal-
ized with the 
 
 
 
-actin expression level. As shown in Fig. 8, the
normalized expression levels of GATA-6 and NFATc1 were
not significantly reduced by CysA or FK 506 (lanes 3 and 4).
Notably, NFATc1 was converted to the high-mobility form af-
ter induction of the differentiated phenotype (Fig. 7, lane 2).
This conversion was reversed by administration of CysA (Fig. 7,
lane 3) and FK506 (Fig. 7, lane 4), which block calcineurin.
These findings might suggest that NFATc1 is dephosphory-
lated by induction of the differentiated phenotype in VSMCs.
 
Expression of markers for differentiated VSMCs 
requires a calcineurin pathway
 
To examine whether a calcineurin pathway is required for the
expression of marker proteins for differentiated VSMCs such
as Sm-MHC and Sm-
 
 
 
-actin, we performed Western blot
analysis. VSMCs were cultured in proliferation medium or
Figure 6.  The amount of GATA-6-
DNA binding is up-regulated by induc-
tion of the differentiated phenotype. (A) 
Nuclear extracts were obtained from 
VSMCs with proliferative (P) or differen-
tiated (D) phenotype. These extracts 
were probed with a radiolabeled oligo-
nucleotide containing the Sm-MHC 
GATA site. Unlabeled competitor DNAs 
were present at a 100-fold molar excess 
as indicated: (lane 4) wild-type Sm-MHC 
GATA (wt); (lane 5) Sm-MHC GATA 
with a mutation (mut). The arrow indi-
cates the complex corresponding to the 
GATA-specific interaction between the 
Sm-MHC GATA site and GATA-6. B, 
EMSA studies using the Sm-MHC-GATA 
probe were performed in nuclear ex-
tracts from VSMCs with differentiated 
(D) phenotype. Equal amounts of the 
anti–GATA-6 antibody (lane 3), the anti–
GATA-4 antibody (lane 2), or normal 
rabbit IgG (lane 1) were added to the 
binding mixture. (C) EMSA studies using 
the probe for Sp-1 were performed in 
nuclear extracts from VSMCs with prolif-
erative (P) or differentiated (D) pheno-
type as indicated. The arrow indicates 
the complex corresponding to the inter-
action between the probe and Sp-1. (D) 
The amount of GATA-6-DNA binding in 
A (lanes 1–3) and that of SP-1-DNA 
binding in C was quantified by densi-
tometry using NIH image 1.61 and the 
relative DNA binding amount (Sm-MHC 
GATA/SP-1) was determined. The rela-
tive DNA binding amount in the prolifer-
ative VSMCs was set at 1.0 in each ex-
periment. Values are the mean   
standard error for three independent ex-
periments. 
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differentiation medium in the presence or absence of 0.5 
 
 
 
g/
ml of CysA and 1 nM of FK506. As shown in Fig. 7, the ex-
pression of Sm-MHC and Sm-
 
 
 
-actin were induced during
differentiation. CysA and FK506 repressed the endogenous
expression of Sm-MHC and Sm-
 
 
 
-actin in VSMCs with the
differentiated phenotype. However, the levels of ubiquitously
expressed 
 
 
 
-actin protein were similar in VSMCs with the
proliferative and differentiated phenotypes, and were not al-
tered by CysA or FK506. Relative expression levels of smooth
muscle–specific proteins normalized with the 
 
 
 
-actin expres-
sion level were shown in Fig. 8. Relative expression levels of
Sm-MHC and Sm-
 
 
 
-actin were significantly reduced by
CysA (Fig. 8, lane 3) and FK506 (Fig. 8, lane 4).
To further examine the role of calcium and calcineurin dur-
ing VSMC differentiation, we performed immunocytochemical
analysis. VSMCs were cultured in proliferation medium (Fig. 9
Figure 7.  Endogenous expression of GATA-6, NFATc1, and 
smooth muscle–specific proteins in VSMCs. VSMCs were cultured 
in proliferation (P) medium (lane 1) or differentiation (D) medium 
(lanes 2–4) in the presence of CysA (lane 3, 0.5  g/ml) or FK506 
(lane 4, 1 nM), or in their absence (lanes 1 and 2). Lysates from 
these cells were subjected to Western blotting using the anti–
GATA-6 antibody, the anti-NFATc1 antibody, the anti–Sm-MHC
antibody, the anti–Sm- -actin antibody, and the anti– -actin
antibody, as indicated.
Figure 8.  Quantitative analysis of the endogenous expression 
of GATA-6, NFATc1, and smooth muscle–specific proteins in 
VSMCs. Immunoblots in Fig. 7 were quantified by densitometry 
using NIH image 1.61 and the relative expression levels of these 
proteins normalized with  -actin expression were determined. 
The relative expression level in VSMCs with a proliferative phe-
notype was set at 1.0. Values are the mean   standard error for 
the three independent experiments. 
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A) or in differentiation medium in the presence of CysA (Fig. 9
D), FK506 (Fig. 9 E), or nifedipine (Fig. 9 F), or in their ab-
sence (Fig. 9, B and C). These cells were then immunostained
with the anti–Sm-MHC antibody. As shown in Fig. 9, brown
positive signals indicating Sm-MHC were absent in cells with
the proliferative phenotype (A), and prominent in cells with the
differentiated phenotype (B). The replacement of the primary
antibody with normal mouse IgG abolished the signals (Fig. 9
C). Both CysA (Fig. 9 D) and FK506 (Fig. 9 E) decreased the
signals in VSMCs with the differentiated phenotype. In addi-
tion, a calcium antagonist, nifedipine, decreased the signals
(Fig. 9 F). These findings further support the idea that calcium
and calcineurin play a role during VSMC differentiation.
 
Discussion
 
The mechanisms that regulate the differentiation of VSMCs
and their phenotype modulation are poorly understood. Pre-
vious studies have shown that a zinc finger transcription fac-
tor, GATA-6, is expressed in VSMCs and is required for the
maintenance of their differentiated phenotype (Morrisey et
al., 1996, 1997; Narita et al., 1996; Suzuki et al., 1996; Perl-
man et al., 1998; Wada et al., 2000). The present study
investigated whether a calcineurin pathway is connected
with GATA-6 and plays a role in the smooth muscle–
specific transcription. We showed that GATA-6 interacted
with NFATc1, a target transcription factor of calcineurin.
GATA-6 and NFATc1 cooperate during the transcription of
the Sm-MHC gene. Induction of VSMCs to the quiescent
phenotype caused nuclear translocation of NFATc1. In dif-
ferentiated VSMCs, blockage of calcineurin down-regulated
the amount of GATA-6-DNA binding as well as the expres-
sion of Sm-MHC and its transcriptional activity.
Calcineurin is a calcium-calmodulin–dependent serine-thre-
onine phosphatase that activates transcription of the NFAT
family. The NFAT family comprises at least four members:
NFATc (NFATc1), NFATp (NFATc2), NFAT3 (NFATc4),
and NFAT4 (NFATc3) (McCaffrey et al., 1993; Northrop et
al., 1994; Ho et al., 1995; Hoey et al., 1995; Masuda et al.,
1995; Park et al., 1996). These factors bind the consensus
DNA sequence through a Rel homology domain (Rooney et
al., 1994; Hoey et al., 1995). VSMCs expressed preferentially
NFATc1 (Boss et al., 1998) and a small amount of NFATc3,
whereas NFATc2 and NFATc4 were not detectable by West-
ern blotting. Although the present study demonstrates the role
of NFATc1 in smooth muscle–specific transcription, our re-
sults do not rule out possible roles of NFATc2-4 in VSMC
differentiation as a recent study reported that vascular develop-
ment in NFATc3/4–null mice was impaired (Graef et al.,
2001). Our results demonstrate that GATA-6 interacted with
NFATc1, and that this interaction required the zinc finger do-
main of GATA-6. Because zinc finger domains are highly con-
served among GATA-4/5/6, these results are compatible with
those in a previous study that a second zinc finger domain of
GATA-4 interacts with NFAT3 (NFATc4). Compatible with
the interaction between GATA-6 and NFATc1, these two fac-
tors synergistically activated the smooth muscle–specific
Sm-MHC promoter. The rat Sm-MHC promoter contains
NFATc1 consensus sequences, GGAAAA, at 
 
 
 
519/
 
 
 
514 rel-
ative to the transcription start site as well as a GATA-6 binding
site at sequences 
 
 
 
810/
 
 
 
805. However, NFATc1 alone was
not sufficient to activate the Sm-MHC promoter in COS cells
in which GATA-6 was not expressed (unpublished data).
These findings suggest that the binding of NFATc1 to an
NFATc1 site within the rat Sm-MHC promoter is weak. At
present, the precise mechanism by which NFATc1 activates
GATA-6–mediated Sm-MHC transcription is unclear. How-
ever, NFATc1 did not affect the Sm-MHC transcriptional ac-
tivity mediated by a mutant GATA-6 unable to interact with
NFATc1. These findings suggest that coactivation of Sm-
MHC transcription by GATA-6 and NFATc1 requires the in-
teraction of these two proteins.
Nuclear NFATc1 interacts with zinc finger transcription
factors GATA-4 in cardiac myocytes and GATA-6 in
VSMCs. We showed that induction of the differentiated phe-
notype increases the amount of GATA-6-DNA binding in a
calcineurin-dependent manner. One of the mechanisms for
the up-regulation of GATA-6-DNA binding may be an in-
crease in the quantity of GATA-6 itself. The other possible
mechanism is that calcineurin activation modifies GATA-6
Figure 9.  CysA and FK506 repressed the endogenous expression of the Sm-MHC in differentiated VSMCs. VSMCs were cultured in prolif-
eration medium (A) or in differentiation medium in the presence of CysA (D, 0.5  g/ml), FK506 (E, 1 nM) or nifedipine (F, 1  M), or in their 
absence (B and C). These cells were subjected to immunostaining with the anti–Sm-MHC antibody. The primary antibody was further incu-
bated with a secondary antibody conjugated with peroxidase (brown signals). The primary antibody was replaced with normal mouse IgG in 
C. The nuclei were counterstained with hematoxylin. Bar, 20  m. 
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posttranslationally as we reported that phosphorylation of
GATA-4 increases its DNA binding activity (Morimoto et
al., 2000). Further study will be needed to clarify these mech-
anisms. Interestingly, the transcriptional coactivator p300 in-
teracts not only with GATA-6 but also with NFAT (Gracia-
Rodriguez and Rao, 1998). The GATA-6/p300 complex in
VSMCs is also up-regulated during induction of the differen-
tiated phenotype (Wada et al., 2000). These findings suggest
that p300, together with GATA-6 and NFATc1, form a large
complex in differentiated VSMCs, and that this complex
plays a role in the maintenance of the differentiated pheno-
type. Our preliminary data suggest that interaction of
GATA-6 with p300 increases the DNA binding activity of
GATA factors. However, further studies are needed to clarify
the precise relationship between the calcineurin-GATA-6
pathway and p300 during VSMC differentiation.
It has been suggested that calcium- and calcineurin-depen-
dent pathways are required for skeletal myogenesis (Salzberg
et al., 1995; Seigneurin-Venin et al., 1996; Friday et al.,
2000). Compatible with this suggestion, the expression of
endogenous Sm-MHC in differentiated VSMCs was down-
regulated by a calcium antagonist, nifedipine. Calcineurin
dephosphorylates the NFAT family members, causing their
translocation to the nucleus (Batiuk and Halloran, 1997).
The present study demonstrated that induction of VSMCs
to the differentiated phenotype caused nuclear translocation
of NFATc1. A physiological concentration of CysA or
FK506, which blocks calcineurin activity, inhibited the en-
dogenous expression of Sm-MHC in differentiated VSMCs.
These findings suggest that calcineurin pathway is activated
during differentiation of VSMCs and required for smooth
muscle–specific Sm-MHC expression. Taken together with
the fact that NFATc1 and GATA-6 coactivated the Sm-
MHC promoter, it seems that a calcineurin pathway is con-
nected with GATA-6 and plays a role in the maintenance of
differentiated phenotype in VSMCs. Further studies regard-
ing the role of the calcineurin pathway in VSMC growth and
differentiation in vivo will facilitate the development of new
therapeutic strategies for vascular diseases in humans.
 
Materials and methods
 
Primary VSMC culture and transfection
 
Primary human aortic VSMCs were obtained from Kurabo Industries Ltd.
and cultured in the medium provided by the manufacturer supplemented
with epithelial growth factor (0.5 ng/ml), basic fibroblast growth factor (2 ng/
ml), insulin (5 
 
 
 
g/ml), and 5% FBS. For induction of the differentiated phe-
notype, VSMCs (passages 6) were cultured in medium with heparin (30 
 
 
 
g/
ml) instead of the above growth factors and with 1% FBS. For transfection,
VSMCs (passages 6) were washed twice with serum-free media and then
transfected with a total of 
 
 
 
5 
 
 
 
g of DNA in 60-mm plates using Lipo-
fectAMINE PLUS (Life Technologies, Inc.) according to the manufacturer’s
recommendation. After a 3-h incubation with DNA-PLUS-LipofectAMIN
complex, VSMCs were cultured in media to induce the differentiated or pro-
liferative phenotype in the presence or absence of CysA (0.5 
 
 
 
g/ml) or
FK506 (1 nM) for 48 h. The cells were then washed twice with ice-cold
phosphate-buffered saline and lysed for luc and CAT assays as described
(Hasegawa et al., 1997; Morimoto et al., 2000). Luc and CAT activities were
determined in the same cell lysate as described previously (Hasegawa et al.,
1997; Morimoto et al., 2000). The relative luc activity was calculated from
the ratio of luc minus background to CAT minus background.
 
Immunocytochemical staining
 
VSMCs (passages 6) were fixed in 3.0% formaldehyde in PBS for 10 min at
room temperature. Immunocytochemical staining for NFATc1 was per-
 
formed using the indirect immunofluorescense method. Cells were incu-
bated with the anti-NFATc1 monoclonal antibody (cat # sc-7294; Santa
Cruz Biotechnology) at a dilution of 1:100. Signals of NFATc1 were de-
tected using the anti–mouse FITC-conjugated secondary antibody (ICN
Biomedicals) at a dilution of 1:500 for 45 min.
Immunocytochemical staining was performed by use of the indirect im-
munoperoxidase method as described previously (Hasegawa et al., 1993).
Endogenous Sm-MHC was detected by the anti–Sm-MHC monoclonal an-
tibody (Sigma-Aldrich) (1:250 dilution), followed by peroxidase-conju-
gated F(ab
 
 
 
)
 
2
 
 fragment of goat anti–mouse IgG (Jackson ImmunoResearch
Laboratories) (1:500 dilution).
 
Plasmid constructs
 
The plasmid construct pSm-MHCCAT consists of the bacterial chloram-
phenicol acetyltransferase (CAT) cDNA driven by 1346-bp of the rat Sm-
MHC gene promoter (Madsen et al., 1996) and was a gift from Dr. Gray K.
Owens (University of Virginia, Charlottesville, VA). The firefly luc cDNA
driven by 836-bp rat Sm-MHC promoter (pwtSm-MHCluc), and that with
mutation of the distal (
 
 
 
810/
 
 
 
805) GATA element (pmutSm-MHCluc)
were described previously (Wada et al., 2000). pRSVluc and pRSVCAT con-
tain luc and CAT cDNA, respectively, driven by Rous sarcoma virus (RSV)
long terminal repeat sequences (Hasegawa et al., 1997; Morimoto et al.,
2000). p
 
 
 
-actinluc contains luc cDNA driven by avian cytoplasmic  -actin
promoter (Hasegawa et al., 1997). The expression plasmids encoding wild-
type human GATA-6 (pwtGATA-6) and mutant human GATA-6 which lacks
the zinc-finger domain (p ZFGATA-6) were kindly donated by Dr. Kenneth
Walsh (Tufts University, Boston, MA) (Suzuki et al., 1996). Plasmid pC-
MV -gal carries the cytomegalovirus promoter/enhancer fused to  -galac-
tosidase cDNA (Kamei et al., 1996). The murine NFATc1 expression plas-
mid (pNFATc1) was a generous gift from Dr. Ken-ichi Arai, University of
Tokyo, Japan (Pan et al., 1997). Plasmids were purified by anion exchange
chromatography (QIAGEN), quantified by the measurement of OD260, and
examined on agarose gels stained with ethidium bromide prior to use.
COS7 cell culture and transfection
COS7 cells (African green monkey kidney cells) were maintained in Dul-
becco’s modified Eagle’s medium with 10% fetal bovine serum. The cells
were washed twice with serum-free medium and then transfected with 6
 g of pNFATc1 and 6  g of either pwtGATA-6 or p ZFGATA-6 in 100-
mm plates using LipofectAMINE (Life Technologies, Inc.). After a 5-h incu-
bation with DNA-LipofectAMINE complex, the cells were washed twice
with serum-free medium and further incubated in the medium with 10%
FBS. 48 h later, nuclear extracts were prepared from these cells.
Immunoprecipitation and Western blotting
200  g of the extracts from COS cells was immunoprecipitated using the
mouse monoclonal antibody against NFATc1 (cat # sc-7294; Santa Cruz Bio-
technology), the rabbit polyclonal anti–GATA-6 antibody (cat # sc-9055;
Santa Cruz Biotechnology) or normal rabbit IgG in low stringency buffer (50
mM Tris, pH 7.4, 150 mM NaCl, 0.5% SDS, Nonidet P-40, 1 mM EDTA, 10
mg/ml aprotinin and leupeptin, and 0.5 mg PMSF) for 16 h at 4 C and incu-
bated with protein G (Sigma-Aldrich) beads for 1 h at 4 C. The precipitate was
washed four times in the same buffer, resuspended in 20  l of SDS-lysis buffer
(20 mM Tris, pH 7.5, 50 mM NaCl, 0.5% SDS,1 mM dithiothreitol), heated to
95 C for 2 min, electrophoresed on an SDS-polyacrylamide gel (8%), trans-
ferred to an Immobilon membrane, reacted with the anti-NFATc1 antibody
(cat # sc-7294), and subsequently detected using horseradish peroxidase-con-
jugated anti–mouse IgG (Jackson ImmunoResearch Laboratories). Signals were
detected using an enhanced chemiluminescence Western blotting detection
system (Amersham Pharmacia Biotech) according to the manufacturer’s in-
structions. Antibodies were stripped using 2% SDS, 62.5 mM Tris, pH 6.8,
100 mM  -mercaptoethanol at 60 C for 30 min. The membrane was reprobed
with goat polyclonal anti–GATA-6 antibody (cat # sc-7244; Santa Cruz Bio-
technology) for 1 h at 25 C. Detection was with horseradish peroxidase-conju-
gated anti–goat IgG (Jackson ImmunoResearch Laboratories) and enhanced
chemiluminescence Western blotting detection system.
Western blotting using the anti–GATA-6 antibody (cat # sc-7244), the
anti–Sm-MHC antibody (Sigma-Aldrich), the anti–Sm- -actin antibody (Daco
Laboratories), the anti– -actin antibody (Sigma-Aldrich), the ant-NFATc1 an-
tibody (cat # sc-7294), the anti-NFATc2 antibody (cat # sc-7296), the anti-
NFATc3 antibody (cat # sc-8405) and the anti-NFATc4 antibody (cat # sc-
1153) was performed with 25  g of cell lysates prepared from VSMCs or
Ramos cells derived from human Burkitt’s lymphoma (cat # sc-2216).
EMSAs
Nuclear extracts were prepared as described previously from VSMCs
which were cultured in 5% FBS containing medium with growth factors orCalcineurin-GATA-6 in SMC transcription | Wada et al. 991
in the 1% low-serum medium without growth factors. Double-stranded
oligonucleotides for GATA-6 were designed based on the rat Sm-MHC up-
stream sequences that contained a GATA motif ( 815/ 810 relative to the
transcription start site). The sequences of the sense strand of these oligonu-
cleotides were as follows: Sm-MHC-GATA, 5 -ACTTTAGGGACGTAAT-
CATCACAGGGAAATCAA-3 ; mutSm-MHC-GATA, 5 -ACTTTAGGGAC-
GTAtagATCACAGGGAAATCAA-3 . Oligonucleotides were synthesized
by Greiner Inc. and purified by SDS-polyacrylamide gel electrophoresis.
Sp-1 consensus double-stranded oligonucleotides were purchased from
Santa Cruz Biotechnology (cat # sc-2502).
EMSAs were carried out as described previously (Hasegawa et al., 1997)
at 4 C for 20 min in 15- l reaction mixtures containing 10  g of nuclear ex-
tract, 0.25 ng ( 20,000 cpm) of radiolabeled double-stranded oligonucle-
otide, 500 ng of poly (dI-dC), 5 mM Tris-HCl, pH 7.5, 1 mM EDTA, 0.5 mM
dithiothreitol, 37.5 mM KCl, and 4% Ficoll 400. For cold competition exper-
iments, a 100-fold molar excess of unlabeled competitor oligonucleotides
was included in the binding reaction mixture. Protein-DNA complexes were
separated by electrophoresis on 4% nondenaturing polyacrylamide gels in
0.25   TBE (100 mM Tris, 100 mM boric acid, and 2 mM EDTA) at 4 C.
Statistical analysis
Data are presented as means   standard error. Statistical comparisons
were performed using unpaired two-tailed Student’s t tests or analysis of
variance with Scheffe’s test where appropriate, with a probability value
 0.05 taken to indicate significance.
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